Criteria for Evaluating Patient Responses to Treatment Modalities for Prostatic Cancer
Urologic Clinics of North AmericaPublished 1 May 1984
Nelson H. Slack, Gerald P. Murphy
Citations85
SJR quartileQ1
SJR score0.88
SNIP1.40
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Criteria for evaluating response to therapy for both early and late stages of prostate cancer, as developed by the National Prostatic Cancer Project, are presented and discussed.
Abstract
Criteria for evaluating response to therapy for both early and late stages of prostate cancer, as developed by the National Prostatic Cancer Project, are presented and discussed. Detection of bone metastases and monitoring of changes in existing bone lesions are critical to these criteria for early and late disease, respectively. The prognosis, or survival experience, of groups of patients for each response category is also discussed.
Keywords
MathematicsEconomics, Econometrics and Finance
Journal of the American Medical AssociationENDOCRINE CONTROL OF PROSTATIC CARCINOMA
374 Citations1950Reed M. Nesbit
For the past eight years the physician has been confronted with problems concerning the selection of the form of endocrine modification most efficacious for the particular needs of the patient, the designation of the most opportune time to institute therapy and the choice of secondary therapy once relapse has occurred.
CancerThe natural history of prostatic cancer
269 Citations1973Willet F. Whitmore
The relevance of the marked variability and unpredictability in the natural history of prostatic cancer thus revealed to treatment decisions and interpretations of the results of treatment in the aging host are indicated.
CancerTreatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone
173 Citations1983Gerald P. Murphy, Sunmolu Beckley +17 more
Analysis within groups having pain versus no pain at entry revealed a marked advantage after 80 weeks for chemotherapy when pain was initially present and a slight advantage during treatment (throughout follow‐up) when the pain was absent.
The Tohoku Journal of Experimental MedicineMeasurements of Size and Weight of Prostate by Means of Transrectal Ultrasonotomography
132 Citations1974HIROKI WATANABE, Dairoku Igari +3 more
Size and weight of prostates were measured in 95 cases by means of transrectal ultrasonotomography and error at this measurement likely to be caused by direction of insertion of the transducer and differences in sonic velocity inside the prostate was confirmed.
UrologyChemotherapy of advanced prostatic cancer Evaluation of response parameters
130 Citations1976Joseph D. Schmidt, Douglas E. Johnson +4 more
A total of 125 patients with progressing advanced prostatic cancer were entered into a chemotherapy study comparing cyclophosphamide, 5-fluorouracil, and standard therapy, and there were more objective responders to cyclophile than standard therapy whether the hemoglobin was initially normal or low.
CancerA critical analysis of response criteria in patients with prostatic cancer treated with CIS-diamminedichloride platinum II
103 Citations1979Alan Yagoda, Robin C. Watson +5 more
In the dosage and schedule used in this protocol, DDP was not an active agent in the treatment of prostatic cancer, and case selection was restricted to patients who had objectively measurable lesions, i.e., nodes, skin, lung and liver metastasis.
The ProstateResponse criteria for the prostate of the USA national prostatic cancer project
96 Citations1980G.P. Murphy, N.H. Slack
Responsibility criteria developed by the National Prostatic Cancer Project to evaluate chemotherapy for advanced disease and as an adjuvant in early disease are described.
Journal of Clinical OncologyDoxorubicin, mitomycin-C, and 5-fluorouracil (DMF) in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate, with a note on the staging of metastatic prostate cancer.
67 Citations1983C. Logothetis, M. L. Samuels +5 more
DMF is an effective treatment of metastatic hormonal refractory prostate cancer, resulting in consistent objective responses, and the staging system employed identifies four clinical categories of metastatics prostate cancer and allows for accurate comparison of diet and stratification of study populations.
British Journal of CancerThe influence of site of metastasis on tumour growth and response to chemotherapy
66 Citations1975N.H. Slack, Irwin D. J. Bross
Analysis of percentage reduction in tumour size after chemotherapy regimens of up to 60 days revealed a significant amount of variation associated with metastatic sites and a non-significant amount associated with sites of primary origin.
CancerThe importance of the stable category for chemotherapy treated patients with advanced and relapsing prostate cancer
62 Citations1980Nelson H. Slack, Arnold Mittelman +2 more
It is felt that in these studies the stable category is valid and useful for determining efficacy of treatment in patients with advancing prostate cancer.
CancerTransrectal ultrasonography of the prostate
59 Citations1984J. Edson Pontes, Hiroshi Ohe +2 more
Staging capabilities in patients with localized prostatic carcinoma are significantly enhanced and prostatic ultrasonography was extremely valuable in detecting capsular involvement.
The Journal of UrologySystemic Treatment of Advanced Prostatic Cancer: Development of a New System for Defining Response
47 Citations1981Dennis L. Citrin, Ashley Cohen +4 more
Based on serial quantitative bone scans, serial measurements of acid phosphatase levels and repeat clinical evaluations a system is proposed for defining response to systemic therapy that is applicable to the majority of patients with metastatic prostatic cancer.
JAMAClinical Cancer of the Prostate
36 Citations1965R.H. Flocks
A study of 4,009 patients with clinical cancer seen during the period from 1926 to Jan 1, 1963 reemphasizes the importance of frequent, routine rectal examinations, with biopsy of suspicious areas in the assessment of the patient and early diagnosis.
The Journal of UrologyThe Value of Nuclear Bone Imaging in Advanced Prostatic Cancer
31 Citations1981Jeffrey J. Pollen, Kenneth Gerber +2 more
The nuclear bone scan is a highly sensitive means of detecting skeletal metastasis in patients with prostatic cancer and can provide information about vertebral metastases that can be important for planning palliative treatment of pain.
UrologyA decade of experience with chemotherapy for prostate cancer
27 Citations1983N.H. Slack, G.P. Murphy
There is some evidence to support the premise that adding antitumor agents to hormones as initial treatment for metastatic disease is more effective than waiting for the ultimate hormone failure, at least in patients with poorer prognosis.
CancerA phase II evaluation of adriamycin and cis-platinum in hormone resistant prostate cancer
25 Citations1982Dennis L. Citrin, Tom F. Hogan
Using the response criteria described here, patients with metastatic prostate cancer without measurable soft tissue disease are eligible for Phase II and III study.
The ProstateAn assessment of bone scans for monitoring osseous metastases in patients being treated for prostate carcinoma
22 Citations1980N.H. Slack, James P. Karr +2 more
Variations in techniques used by each of 9 treatment centers, as well as the National Cancer Institute, were compared and most consistently correlated with disease changes were prostatic acid phosphatase, as determined by counter‐immuno‐electrophoresis, and the isoenzyme of bone alkalineosphatase.
The ProstateStable versus partial response in advanced prostate cancer
22 Citations1984Nelson H. Slack, Mark F. Brady +1 more
Comparisons of survival patterns for those patients categorized as stable or partial regression revealed no statistically significant differences between them, and the similarity of survival for the stable and partial regression categories indicates that the stable category represents more than a segment of the population with slowly progressing disease and can be taken as an indicator of response to therapy.
Journal of Surgical OncologyThe addition of chemotherapy to hormonal therapy for treatment of patients with metastatic carcinoma of the prostate
16 Citations1983Robert P. Gibbons, S. Beckley +17 more
Objective response rates, response duration, or survival experiences were not demonstrably different between treatment arms, either for all patients or within good or poor prognosis groups determined by initial pain or acid phosphatase level.